Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168906 · ClinicalTrials.gov registry record · Phase 2
Renal AL Amyloid Involvement and NEOD001
A Phase 2 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03168906 is a Phase 2 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT03168906, a Phase 2 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a maintained hematologic response to their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[ASCT\]) and have persistent renal dysfunction.
Interventions
- DRUG Placebo
- DRUG NEOD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2019-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168906
The ClinicalTrials.gov registry entry for NCT03168906 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03168906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168906 about?
NCT03168906 is a clinical study titled "Renal AL Amyloid Involvement and NEOD001". This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a maintained hematologic response to their most recent treatment for AL amyl...
What is the current status of trial NCT03168906?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-07-05. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT03168906?
The interventions under investigation include: Placebo (DRUG), NEOD001 (DRUG).
Who is sponsoring clinical trial NCT03168906?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.